CHRDL2 and cancer: Thus, inhibition of BMP signalling through CHRDL2 or other antagonists may indeed force cancer cells in the colon into a more stem‐like state, and while this may not increase the proliferation rate, it could increase the longevity and survival of these cells during treatment with DNA‐damaging therapies.